Search | Clinical Trials Finder

Conditions: Tumors, Lymphoma
Interventions: CNF2024; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Scottsdale, Arizona • New Haven, Connecticut • San Antonio, Texas

Conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus
Interventions: Surovatamig; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Fullerton, California • St Louis, Missouri + 2 more

Conditions: Sickle Cell Disease (SCD)
Interventions: crizanlizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 12
States / cities: Orange, Florida • Tampa, Florida • Atlanta, Georgia + 9 more

Conditions: Psoriasis
Interventions: Calcipotriene 0.005% Foam; Drug
Lead sponsor: Mayne Pharma International Pty Ltd; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: San Diego, California • Ormond Beach, Florida • Tampa, Florida + 6 more

Conditions: Sickle Cell Disease
Interventions: L-citrulline tablets, 1000 mg; Drug
Lead sponsor: Angiogenix; Industry
Eligibility: 10 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Kidney Injury
Interventions: CXA-10, CXA-10 placebo; Drug · Other
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Colitis, Ulcerative
Interventions: Anrukinzumab, placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 19 more

Conditions: Diabetes Mellitus, Type 1
Interventions: AT247, NovoLog, Fiasp; Drug
Lead sponsor: Arecor Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Hypertension
Interventions: Aliskiren 3.125 mini-tablets; Drug
Lead sponsor: Novartis; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Healthy
Interventions: IW-1973, Matching Placebo Tablet; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: TAK-418, TAK-418 Matching Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Glendale, California • Salt Lake City, Utah

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma, Mantle-Cell Lymphoma, Waldenstrom Macroglobulinemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions: SNS-062; Drug
Lead sponsor: Sunesis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 11
States / cities: Orange, California • San Diego, California • Tampa, Florida + 7 more

Conditions: Dyslipidemia
Interventions: AZD8233 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Chula Vista, California • Glendale, California • La Mesa, California + 4 more

Conditions: Amyloid Cardiomyopathy, Transthyretin-Related
Interventions: AG10 oral tablet, Placebo Oral Tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Type 2 Diabetes Mellitus, Diabetes
Interventions: REMD-477; Biological
Lead sponsor: REMD Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Miami, Florida • San Antonio, Texas • Renton, Washington

Conditions: Myotonic Dystrophy 1
Interventions: PGN-EDODM1 for infusion, Placebo; Drug · Other
Lead sponsor: PepGen Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Irvine, California • Palo Alto, California • Atlanta, Georgia + 4 more

Conditions: Healthy Adult Volunteers
Interventions: BMS-986090, Placebo matching with BMS-986090, Keyhole limpet hemocyanin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Healthy
Interventions: Technosphere Insulin Inhalation Powder using the Gen2C inhaler, Regular Human Insulin; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Heart Failure
Interventions: THRV-1268, Placebo; Drug
Lead sponsor: Thryv Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Major Depressive Disorder, Anhedonia
Interventions: ALTO-203 25 μg, ALTO-203 75 μg, Placebo; Drug
Lead sponsor: Alto Neuroscience; Industry
Eligibility: 25 Years to 64 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 15
States / cities: Tucson, Arizona • Oceanside, California • Torrance, California + 12 more

Conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
Interventions: Tiragolumab, Daratumumab/rHuPH20, Rituximab, Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 9
States / cities: Denver, Colorado • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Type 2 Diabetes Mellitus
Interventions: PE0139 Injection, Placebo Injection; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Anniston, Alabama • Huntington Park, California • Bradenton, Florida + 3 more

Conditions: Cancer
Interventions: Trametinib, Dabrafenib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 10
States / cities: Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
Interventions: VK0214, Placebo; Drug · Other
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Palo Alto, California • Gainesville, Florida • Baltimore, Maryland + 1 more

Search by objective public record fields.

Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age

Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants

PD, PK, and Safety of ALTO-203 in Patients With MDD

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN